Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 6:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Gadolinium Clear all
Recruiting Phase 2 Interventional

Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System

NCT03270059
View directory record Official record
Conditions
Central Nervous System Neoplasm, Cranial Nerve Disorder, Metastatic Malignant Neoplasm in the Brain
Interventions
Ferumoxytol, Gadolinium, Magnetic Resonance Imaging
Drug · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
10 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Jul 21, 2026, 6:54 AM EDT
Completed Phase 1 Interventional

Comparison of Magnetic Resonance Angiography and Standard Angiography in Diagnosing Atherosclerosis

NCT00001946
View directory record Official record
Conditions
Atherosclerosis
Interventions
Magnetic resonance angiography
Procedure
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 21, 2026, 6:54 AM EDT
Completed Phase 1 Interventional

Motexafin Gadolinium With MRI-Guided Surgery in Treating Patients With High-Grade Gliomas

NCT00003410
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
motexafin gadolinium, magnetic resonance imaging, surgical procedure
Drug · Procedure
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2013 · Synced Jul 21, 2026, 6:54 AM EDT
Withdrawn No phase listed Observational

QSM and Regional DCE MRI Permeability Using GOCART Technique

NCT03091803
View directory record Official record
Conditions
Intracranial Neoplasm
Interventions
Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Gadobenate Dimeglumine, Gadoterate Meglumine, Magnetic Resonance Imaging
Device · Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 4, 2021 · Synced Jul 21, 2026, 6:54 AM EDT
Completed No phase listed Observational Results available

Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate Renal Insufficiency After the Administration of Magnevist

NCT00744939
View directory record Official record
Conditions
Fibrosis, Kidney Failure, Renal Insufficiency
Interventions
Gadopentetate dimeglumine (Magnevist, BAY86-4882)
Drug
Lead sponsor
Bayer
Industry
Eligibility
2 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
26
States / cities
Phoenix, Arizona • Chula Vista, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2014 · Synced Jul 21, 2026, 6:54 AM EDT
Completed Not applicable Interventional

Indirect Magnetic Resonance Lymphangiography of the Head and Neck Region Using Conventional Gadolinium-based Contrast

NCT00230295
View directory record Official record
Conditions
Head and Neck Cancer, Head and Neck Cancers
Interventions
IMR LAG
Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 26, 2010 · Synced Jul 21, 2026, 6:54 AM EDT
Completed Not applicable Interventional Results available

Dispersal Pattern for Spine Injections (Gadolinium Contrast)

NCT02217280
View directory record Official record
Conditions
Cervical Radiculopathy
Interventions
Injection with Gadolinium
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 27, 2017 · Synced Jul 21, 2026, 6:54 AM EDT
Completed Phase 1 Interventional

Motexafin Gadolinium Plus Radiation Therapy in Treating Children With Newly Diagnosed Brain Stem Glioma

NCT00003909
View directory record Official record
Conditions
Untreated Childhood Brain Stem Glioma
Interventions
motexafin gadolinium, radiation therapy, pharmacological study
Drug · Radiation · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Arcadia, California
Source: ClinicalTrials.gov public record
Updated Jan 15, 2013 · Synced Jul 21, 2026, 6:54 AM EDT
Completed No phase listed Observational

Syngo NATIVE Contrast Enhanced 3D MRA on 3T Verio Magnet

NCT02065648
View directory record Official record
Conditions
Vascular Disease
Interventions
Not listed
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Jul 21, 2026, 6:54 AM EDT
Completed No phase listed Observational

Pilot Study of Cardiac MR in Patients With Muscular Dystrophy

NCT02921321
View directory record Official record
Conditions
Muscular Dystrophies, Cardiac Fibrosis, Genetic Diseases, Inborn, Musculoskeletal Diseases
Interventions
Not listed
Lead sponsor
Children's National Research Institute
Other
Eligibility
6 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Jul 21, 2026, 6:54 AM EDT
Completed Phase 2 Interventional

A Study of Motexafin Gadolinium for the Treatment of Relapsed or Refractory Multiple Myeloma

NCT00096837
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Motexafin Gadolinium Injection
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 7, 2006 · Synced Jul 21, 2026, 6:54 AM EDT
Completed No phase listed Observational

Magnetic Resonance Imaging of the Blood Vessels of the Heart

NCT00001638
View directory record Official record
Conditions
Heart Disease
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
2,916 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2009
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 3, 2022 · Synced Jul 21, 2026, 6:54 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma

NCT00305864
View directory record Official record
Conditions
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
Interventions
3-Dimensional Conformal Radiation Therapy, Motexafin Gadolinium, Temozolomide
Radiation · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
106
States / cities
Mobile, Alabama • Scottsdale, Arizona • Tucson, Arizona + 73 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2018 · Synced Jul 21, 2026, 6:54 AM EDT
Withdrawn Phase 4 Interventional

Use of Gadolinium in CT Pulmonary Angiography

NCT02234375
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
Gadolinium
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
20 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 16, 2020 · Synced Jul 21, 2026, 6:54 AM EDT
Completed Phase 1 Interventional

A Study of Motexafin Gadolinium (MGd) in Combination With Docetaxel and Cisplatin for Treatment of Non-Small Cell Lung Cancer (NSCLC)

NCT00102505
View directory record Official record
Conditions
Non-Small-Cell Lung Carcinoma, Carcinoma, Bronchogenic
Interventions
Motexafin Gadolinium Injection
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 2, 2009 · Synced Jul 21, 2026, 6:54 AM EDT
Recruiting Phase 2 Interventional

Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques

NCT02784210
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Methylprednisolone, Prednisone
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 120 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Jul 21, 2026, 6:54 AM EDT
Completed Phase 1 Interventional

A Study of Motexafin Gadolinium and Temozolomide for the Treatment of Malignant Gliomas

NCT00080054
View directory record Official record
Conditions
Glioma, Glioblastoma, Astrocytoma, Oligodendroglioma, Brain Neoplasm
Interventions
Motexafin Gadolinium Injection
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 2, 2009 · Synced Jul 21, 2026, 6:54 AM EDT
Completed Phase 2 Interventional

Motexafin Gadolinium Plus Radiation Therapy to the Brain in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

NCT00022256
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
motexafin gadolinium, radiation therapy
Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 17, 2013 · Synced Jul 21, 2026, 6:54 AM EDT
Completed Phase 1 Interventional

Radiation Therapy in Treating Patients With Bile Duct, Gallbladder, or Pancreatic Cancer

NCT00003411
View directory record Official record
Conditions
Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Pancreatic Cancer
Interventions
motexafin gadolinium, radiation therapy
Drug · Radiation
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
3
States / cities
Lebanon, New Hampshire • Pittsburgh, Pennsylvania • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 17, 2016 · Synced Jul 21, 2026, 6:54 AM EDT
Terminated Phase 2 Interventional Results available

Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma

NCT01549886
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
Y-90-Zevalin, Moxtezafin Gadolinium, Rituximab
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
9
States / cities
Berkeley, California • Burbank, California • Daytona Beach, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2021 · Synced Jul 21, 2026, 6:54 AM EDT
Completed Phase 1 Interventional

Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer

NCT00005065
View directory record Official record
Conditions
Stage IIIA Non-small Cell Lung Cancer
Interventions
paclitaxel, carboplatin, motexafin gadolinium, conventional surgery, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 3, 2013 · Synced Jul 21, 2026, 6:54 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis

NCT06220669
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
LY3541860, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
6
States / cities
Gulf Breeze, Florida • Winter Park, Florida • Northbrook, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Jul 21, 2026, 6:54 AM EDT
Withdrawn Early Phase 1 Interventional

DTPA (Diethylenetriaminepenta-acetate) Chelation for Symptoms After Gadolinium-assisted MRI Exposure

NCT05359835
View directory record Official record
Conditions
Gadolinium Deposition Disease
Interventions
Calcium DTPA and Zinc DTPA
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Jul 21, 2026, 6:54 AM EDT
Completed Not applicable Interventional Results available

Long-Term Retention of Gadolinium in Bone

NCT01853163
View directory record Official record
Conditions
Focus: Long-term Retention of Gadolinium-based Contrast Agent
Interventions
Gadolinium analysis in bone and tissue samples
Procedure
Lead sponsor
Navitas Life Sciences GmbH
Industry
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Jul 21, 2026, 6:54 AM EDT